Tag Archives: Before

Opioid for Depression Comes Before FDA Panel

An investigational drug that targets the opioid system for major depressive disorder will be reviewed in an FDA advisory committee meeting Thursday, and briefing documents from agency staff suggest the product won’t have an easy time. The safety and efficacy of ALKS 5461, a combination of buprenorphine and samidorphan intended to be used as adjunctive… Read More »